{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:19:46Z","timestamp":1787170786971,"version":"build-2736575974"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Gastro"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s11938-018-0177-z","type":"journal-article","created":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T20:24:29Z","timestamp":1519849469000},"page":"147-164","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Biosimilars in the Treatment of Inflammatory Bowel Disease: Supporting Evidence in 2017"],"prefix":"10.1007","volume":"16","author":[{"given":"Frank I.","family":"Scott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary R.","family":"Lichtenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,1]]},"reference":[{"issue":"1","key":"177_CR1","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1136\/gutjnl-2012-303376","volume":"63","author":"ME Valk van der","year":"2014","unstructured":"van der Valk ME, Mangen MJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFalpha therapy: results from the COIN study. Gut. 2014;63(1):72\u20139. https:\/\/doi.org\/10.1136\/gutjnl-2012-303376 .","journal-title":"Gut"},{"key":"177_CR2","unstructured":"Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Santa Monica, CA: RAND Corporation; [Available from: https:\/\/www.rand.org\/pubs\/perspectives\/PE264.html ."},{"issue":"4","key":"177_CR3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.yebeh.2010.05.015","volume":"18","author":"SL Helmers","year":"2010","unstructured":"Helmers SL, Paradis PE, Manjunath R, Duh MS, Lafeuille MH, Latremouille-Viau D, et al. Economic burden associated with the use of generic antiepileptic drugs in the United States. Epilepsy Behav. 2010;18(4):437\u201344. https:\/\/doi.org\/10.1016\/j.yebeh.2010.05.015 .","journal-title":"Epilepsy Behav"},{"issue":"3","key":"177_CR4","doi-asserted-by":"publisher","first-page":"e278","DOI":"10.1097\/MJT.0000000000000282","volume":"24","author":"RJ Straka","year":"2017","unstructured":"Straka RJ, Keohane DJ, Liu LZ. Potential clinical and economic impact of switching branded medications to generics. Am J Ther. 2017;24(3):e278\u2013e89. https:\/\/doi.org\/10.1097\/MJT.0000000000000282 .","journal-title":"Am J Ther"},{"issue":"11","key":"177_CR5","doi-asserted-by":"publisher","first-page":"e502","DOI":"10.1016\/S1470-2045(16)30374-6","volume":"17","author":"H Schellekens","year":"2016","unstructured":"Schellekens H, Smolen JS, Dicato M, Rifkin RM. Safety and efficacy of biosimilars in oncology. Lancet Oncol. 2016;17(11):e502\u2013e9. https:\/\/doi.org\/10.1016\/S1470-2045(16)30374-6 .","journal-title":"Lancet Oncol"},{"issue":"4","key":"177_CR6","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/cam4.258","volume":"3","author":"LH Camacho","year":"2014","unstructured":"Camacho LH, Frost CP, Abella E, Morrow PK, Whittaker S. Biosimilars 101: considerations for U.S. oncologists in clinical practice. Cancer Med. 2014;3(4):889\u201399. https:\/\/doi.org\/10.1002\/cam4.258 .","journal-title":"Cancer Med"},{"issue":"12","key":"177_CR7","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1002\/bit.26438","volume":"114","author":"CF Kirchhoff","year":"2017","unstructured":"Kirchhoff CF, Wang XM, Conlon HD, Anderson S, Ryan AM, Bose A. Biosimilars: key regulatory considerations and similarity assessment tools. Biotechnol Bioeng. 2017;114(12):2696\u2013705. https:\/\/doi.org\/10.1002\/bit.26438 .","journal-title":"Biotechnol Bioeng"},{"key":"177_CR8","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products 2014 [updated 10\/23\/2014. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/10\/WC500176768.pdf ."},{"key":"177_CR9","unstructured":"Department of Health US Human Services, Food and Drug Administration, Center for Drug Evaluation Research (CDER), Center for Biologics Evaluation and Research (CBER). Quality considerations in demonstrating biosimilarity to a reference protein product: guidance for industry. 2015 [Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM291134.pdf"},{"issue":"4","key":"177_CR10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.biologicals.2014.05.005","volume":"42","author":"BG Feagan","year":"2014","unstructured":"Feagan BG, Choquette D, Ghosh S, Gladman DD, Ho V, Meibohm B, et al. The challenge of indication extrapolation for infliximab biosimilars. Biologicals. 2014;42(4):177\u201383. https:\/\/doi.org\/10.1016\/j.biologicals.2014.05.005 .","journal-title":"Biologicals"},{"key":"177_CR11","unstructured":"U.S. Food and Drug Administration. FDA approves Inflectra, a biosimilar to Remicade Silver Spring (MD)2016 [Available from: https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm494227.htm ."},{"issue":"10","key":"177_CR12","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","volume":"72","author":"W Park","year":"2013","unstructured":"Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605\u201312. https:\/\/doi.org\/10.1136\/annrheumdis-2012-203091 . This clinical trial was the first demonstrating the efficacy of CT-P13 in ankylosing spondylitis. The primary findings of similar efficacy, safety, and immunogenicity compared to reference infliximab were used as significant evidence in the approval of CT-P13 for ankylosing spondylitis as well as for indication extrapolation to inflammatory bowel disease.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"177_CR13","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","volume":"72","author":"DH Yoo","year":"2013","unstructured":"Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613\u201320. https:\/\/doi.org\/10.1136\/annrheumdis-2012-203090 . This clinical trial, like PLANETAS, demonstrated similar efficacy, safety and immunogenicity of CT-P13 in rheumatoid arthritis. These findings were also important in the approval of CT-P13 and subsequent indication extrapolation to inflammatory bowel disease.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"177_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1136\/annrheumdis-2015-207764","volume":"76","author":"JY Choe","year":"2017","unstructured":"Choe JY, Prodanovic N, Niebrzydowski J, Staykov I, Dokoupilova E, Baranauskaite A, et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017;76(1):58\u201364. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207764 .","journal-title":"Ann Rheum Dis"},{"key":"177_CR15","unstructured":"U.S. Food and Drug Administration. Drugs@FDA: FDA approved drug products: Renflexis Silver Spring (MD)2017 [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2017\/761054Orig1s000ltr.pdf ."},{"key":"177_CR16","unstructured":"U.S. Food and Drug Administration. FDA approves Amjevita, a biosimilar to Humira 2016 [Available from: https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm522243.htm ."},{"issue":"10","key":"177_CR17","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1136\/annrheumdis-2016-210459","volume":"76","author":"S Cohen","year":"2017","unstructured":"Cohen S, Genovese MC, Choy E, Perez-Ruiz F, Matsumoto A, Pavelka K, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis. 2017;76(10):1679\u201387. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210459 .","journal-title":"Ann Rheum Dis"},{"key":"177_CR18","unstructured":"U.S. FOod and Drug Administration. Drugs@FDA: FDA approved drug products: Cyltezo 2017 [Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761058 ."},{"issue":"Suppl 2","key":"177_CR19","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/annrheumdis-2017-eular.3405","volume":"76","author":"S Cohen","year":"2017","unstructured":"Cohen S, Alonso-Ruiz A, Klimiuk PA, Lee E, Peter N, Sonderegger I, et al. FRI0189\u00a0Similar efficacy and safety of biosimilar candidate BI 695501 and adalimumab originator reference product in patients with moderate to severe active rheumatoid arthritis: 24 week results from a phase III clinical study (voltaire\u00ae-ra). Ann Rheum Dis. 2017;76(Suppl 2):553.","journal-title":"Ann Rheum Dis"},{"key":"177_CR20","unstructured":"Brennan Z. FDA approves 6th biosimilar in US, second for Humira 2017 [Available from: http:\/\/www.raps.org\/Regulatory-Focus\/News\/2017\/08\/28\/28340\/FDA-Approves-6th-Biosimilar-in-US-Second-for-Humira\/ ."},{"issue":"1","key":"177_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nrgastro.2016.155","volume":"14","author":"S Danese","year":"2016","unstructured":"Danese S, Bonovas S, Peyrin-Biroulet L. Biosimilars in IBD: from theory to practice. Nat Rev Gastroenterol Hepatol. 2016;14(1):22\u201331. https:\/\/doi.org\/10.1038\/nrgastro.2016.155 .","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"12","key":"177_CR22","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.cgh.2016.05.023","volume":"14","author":"S Ben-Horin","year":"2016","unstructured":"Ben-Horin S, Vande Casteele N, Schreiber S, Lakatos PL. Biosimilars in inflammatory bowel disease: facts and fears of extrapolation. Clin Gastroenterol Hepatol. 2016;14(12):1685\u201396. https:\/\/doi.org\/10.1016\/j.cgh.2016.05.023 .","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"177_CR23","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s10620-014-3392-z","volume":"60","author":"YS Kang","year":"2015","unstructured":"Kang YS, Moon HH, Lee SE, Lim YJ, Kang HW. Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci. 2015;60(4):951\u20136. https:\/\/doi.org\/10.1007\/s10620-014-3392-z .","journal-title":"Dig Dis Sci"},{"issue":"9","key":"177_CR24","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1517\/14712598.2015.1064893","volume":"15","author":"K Farkas","year":"2015","unstructured":"Farkas K, Rutka M, Balint A, Nagy F, Bor R, Milassin A, et al. Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn\u2019s disease and ulcerative colitis\u2014experiences from a single center. Expert Opin Biol Ther. 2015;15(9):1257\u201362. https:\/\/doi.org\/10.1517\/14712598.2015.1064893 .","journal-title":"Expert Opin Biol Ther"},{"issue":"11","key":"177_CR25","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1093\/ecco-jcc\/jjw085","volume":"10","author":"K Farkas","year":"2016","unstructured":"Farkas K, Rutka M, Golovics PA, Vegh Z, Lovasz BD, Nyari T, et al. Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis. J Crohn's Colitis. 2016;10(11):1273\u20138. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjw085 .","journal-title":"J Crohn's Colitis"},{"issue":"Suppl 1","key":"177_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1586\/17474124.2015.1091309","volume":"9","author":"SH Park","year":"2015","unstructured":"Park SH, Kim YH, Lee JH, Kwon HJ, Lee SH, Park DI, et al. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev Gastroenterol Hepatol. 2015;9(Suppl 1):35\u201344. https:\/\/doi.org\/10.1586\/17474124.2015.1091309 .","journal-title":"Expert Rev Gastroenterol Hepatol."},{"issue":"Suppl 1","key":"177_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1586\/17474124.2015.1091308","volume":"9","author":"J Jahnsen","year":"2015","unstructured":"Jahnsen J, Detlie TE, Vatn S, Ricanek P. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: a Norwegian observational study. Expert Rev Gastroenterol Hepatol. 2015;9(Suppl 1):45\u201352. https:\/\/doi.org\/10.1586\/17474124.2015.1091308 .","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"12","key":"177_CR28","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1111\/jgh.12997","volume":"30","author":"YS Jung","year":"2015","unstructured":"Jung YS, Park DI, Kim YH, Lee JH, Seo PJ, Cheon JH, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol. 2015;30(12):1705\u201312. https:\/\/doi.org\/10.1111\/jgh.12997 .","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"177_CR29","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/ecco-jcc\/jjv220","volume":"10","author":"KB Gecse","year":"2016","unstructured":"Gecse KB, Lovasz BD, Farkas K, Banai J, Bene L, Gasztonyi B, et al. Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort. J Crohn\u2019s Colit. 2016;10(2):133\u201340. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjv220 .","journal-title":"J Crohn\u2019s Colit"},{"issue":"2","key":"177_CR30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/ecco-jcc\/jjv233","volume":"10","author":"J Sieczkowska","year":"2016","unstructured":"Sieczkowska J, Jarzebicka D, Banaszkiewicz A, Plocek A, Gawronska A, Toporowska-Kowalska E, et al. Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease. Preliminary observations. J Crohn's Colitis. 2016;10(2):127\u201332. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjv233 .","journal-title":"J Crohn's Colitis"},{"issue":"9","key":"177_CR31","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.3109\/00365521.2016.1149883","volume":"51","author":"R Keil","year":"2016","unstructured":"Keil R, Wasserbauer M, Zadorova Z, Hajer J, Drastich P, Wohl P, et al. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn\u2019s disease and ulcerative colitis. Scand J Gastroenterol. 2016;51(9):1062\u20138. https:\/\/doi.org\/10.3109\/00365521.2016.1149883 .","journal-title":"Scand J Gastroenterol"},{"issue":"11","key":"177_CR32","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1093\/ecco-jcc\/jjw087","volume":"10","author":"LJ Smits","year":"2016","unstructured":"Smits LJ, Derikx LA, de Jong DJ, Boshuizen RS, van Esch AA, Drenth JP, et al. Clinical outcomes following a switch from Remicade(R) to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. J Crohn's Colitis. 2016;10(11):1287\u201393. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjw087 .","journal-title":"J Crohn's Colitis"},{"issue":"2","key":"177_CR33","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/MIB.0000000000000995","volume":"23","author":"G Fiorino","year":"2017","unstructured":"Fiorino G, Manetti N, Armuzzi A, Orlando A, Variola A, Bonovas S, et al. The PROSIT-BIO cohort: a prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar. Inflamm Bowel Dis. 2017;23(2):233\u201343. https:\/\/doi.org\/10.1097\/MIB.0000000000000995 .","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"177_CR34","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/ecco-jcc\/jjw166","volume":"11","author":"LC Buer","year":"2017","unstructured":"Buer LC, Moum BA, Cvancarova M, Warren DJ, Medhus AW, Hoivik ML. Switching from Remicade(R) to Remsima(R) is well tolerated and feasible: a prospective, open-label study. J Crohn's Colitis. 2017;11(3):297\u2013304. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjw166 .","journal-title":"J Crohn's Colitis"},{"issue":"5","key":"177_CR35","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s10620-017-4511-4","volume":"62","author":"F Arguelles-Arias","year":"2017","unstructured":"Arguelles-Arias F, Guerra Veloz MF, Perea Amarillo R, Vilches-Arenas A, Castro Laria L, Maldonado Perez B, et al. Effectiveness and safety of CT-P13 (biosimilar infliximab) in patients with inflammatory bowel disease in real life at 6 months. Dig Dis Sci. 2017;62(5):1305\u201312. https:\/\/doi.org\/10.1007\/s10620-017-4511-4 .","journal-title":"Dig Dis Sci"},{"issue":"6","key":"177_CR36","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1093\/ecco-jcc\/jjw216","volume":"11","author":"V Razanskaite","year":"2017","unstructured":"Razanskaite V, Bettey M, Downey L, Wright J, Callaghan J, Rush M, et al. Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme. J Crohn\u2019s Colitis. 2017;11(6):690\u20136. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjw216 .","journal-title":"J Crohn\u2019s Colitis"},{"key":"177_CR37","doi-asserted-by":"crossref","unstructured":"Smits LJT, Grelack A, Derikx L, de Jong DJ, van Esch AAJ, Boshuizen RS, et al. Long-term clinical outcomes after switching from Remicade(R) to biosimilar ct-p13 in inflammatory bowel disease. Digestive diseases and sciences. 2017.","DOI":"10.1007\/s10620-017-4661-4"},{"key":"177_CR38","doi-asserted-by":"crossref","unstructured":"Gonczi L, Gecse KB, Vegh Z, Kurti Z, Rutka M, Farkas K, et al. Long-term efficacy, safety, and immunogenicity of biosimilar infliximab after one year in a prospective nationwide cohort. Inflammatory bowel diseases. 2017.","DOI":"10.1097\/MIB.0000000000001237"},{"issue":"12","key":"177_CR39","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1080\/00365521.2017.1369561","volume":"52","author":"A Eberl","year":"2017","unstructured":"Eberl A, Huoponen S, Pahikkala T, Blom M, Arkkila P, Sipponen T. Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients. Scand J Gastroenterol. 2017;52(12):1348\u201353. https:\/\/doi.org\/10.1080\/00365521.2017.1369561 .","journal-title":"Scand J Gastroenterol"},{"issue":"11","key":"177_CR40","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1097\/MEG.0000000000000953","volume":"29","author":"F Arguelles-Arias","year":"2017","unstructured":"Arguelles-Arias F, Guerra Veloz MF, Perea Amarillo R, Vilches-Arenas A, Castro Laria L, Maldonado Perez B, et al. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results. Eur J Gastroenterol Hepatol. 2017;29(11):1290\u20135. https:\/\/doi.org\/10.1097\/MEG.0000000000000953 .","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"177_CR41","doi-asserted-by":"crossref","unstructured":"D\u00f6rner T, Kay J. Biosimilars in rheumatology: current perspectives and lessons learnt. Nat Rev Rheumatol. 2015;11(12):713\u2013724.","DOI":"10.1038\/nrrheum.2015.110"},{"key":"177_CR42","unstructured":"U.S. Department of Health and Human Services, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research (CBER). Considerations in demonstrating interchangeability with a reference product: guidance for industry. Silver Spring (MD); 2017 January 2017."},{"issue":"10086","key":"177_CR43","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","volume":"389","author":"KK Jorgensen","year":"2017","unstructured":"Jorgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304\u201316. https:\/\/doi.org\/10.1016\/S0140-6736(17)30068-5 . The NORSWITCH trial is the largest conducted trial of biosimilar interchangeability in autoimmune diseases. This pivotal study provides the first evidence that induction with an originator biologic and subsequent transition to a biosimilar may be safe. Further research is ongoing regarding multiple changes between biosimialrs as well as interchangeability for biosimilars other than CT-P13.","journal-title":"Lancet"},{"issue":"7","key":"177_CR44","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa020888","volume":"348","author":"F Baert","year":"2003","unstructured":"Baert F, Noman M, Vermeire S, Van Assche G, D\u2019Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease. N Engl J Med. 2003;348(7):601\u20138. https:\/\/doi.org\/10.1056\/NEJMoa020888 .","journal-title":"N Engl J Med"},{"issue":"4","key":"177_CR45","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1053\/gast.2003.50145","volume":"124","author":"RJ Farrell","year":"2003","unstructured":"Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn\u2019s disease: a randomized controlled trial. Gastroenterology. 2003;124(4):917\u201324. https:\/\/doi.org\/10.1053\/gast.2003.50145 .","journal-title":"Gastroenterology"},{"issue":"9317","key":"177_CR46","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(02)08512-4 .","journal-title":"Lancet"},{"issue":"7","key":"177_CR47","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/S1542-3565(04)00238-1","volume":"2","author":"SB Hanauer","year":"2004","unstructured":"Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2004;2(7):542\u201353. https:\/\/doi.org\/10.1016\/S1542-3565(04)00238-1 .","journal-title":"Clin Gastroenterol Hepatol"},{"key":"177_CR48","unstructured":"Identifier NCT03210259, This trial compares BI 695501 and Humira\u00ae in patients with a long-term disease that causes red, scaly patches on the skin (Plaque Psoriasis). The trial looks at the way the body takes up the drugs and how effective and safe they are (VOLTAIRE-X) [Internet]. ClinicalTrials.gov . 2017 [cited October 10th, 2017]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03210259?term=BI695501&rank=9 ."},{"issue":"12","key":"177_CR49","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1007\/s12325-016-0431-5","volume":"33","author":"H Cohen","year":"2017","unstructured":"Cohen H, Beydoun D, Chien D, Lessor T, McCabe D, Muenzberg M, et al. Awareness, knowledge, and perceptions of biosimilars among specialty physicians. Adv Ther. 2017;33(12):2160\u201372. https:\/\/doi.org\/10.1007\/s12325-016-0431-5 .","journal-title":"Adv Ther"},{"key":"177_CR50","unstructured":"Fein AJ. Remicade: a case study in how U.S. pricing and reimbursement curb adoption of biosimilars 2017 [Available from: http:\/\/www.drugchannels.net\/2017\/09\/remicade-case-study-in-how-us-pricing.html ."},{"key":"177_CR51","doi-asserted-by":"crossref","unstructured":"Malickova K, Duricova D, Kolar M, Bortlik M, Hruba V, Machkova N, et al. No difference in immunogenicity of the original and biosimilar infliximab in patients with inflammatory bowel disease: short-term results. Proceedings from the European Crohn\u2019s and Colitis Organisation; March 16\u201319. 2016:P311.","DOI":"10.1016\/S0016-5085(16)31446-9"},{"issue":"3","key":"177_CR52","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s40259-017-0219-4","volume":"31","author":"W Reinisch","year":"2017","unstructured":"Reinisch W, Jahnsen J, Schreiber S, Danese S, Panes J, Balsa A, et al. Evaluation of the cross-reactivity of antidrug antibodies to CT-P13 and infliximab reference product (Remicade): an analysis using immunoassays tagged with both agents. BioDrugs. 2017;31(3):223\u201337. https:\/\/doi.org\/10.1007\/s40259-017-0219-4 .","journal-title":"BioDrugs"},{"issue":"4","key":"177_CR53","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1097\/MIB.0000000000000709","volume":"22","author":"A Gils","year":"2016","unstructured":"Gils A, Van Stappen T, Dreesen E, Storme R, Vermeire S, Declerck PJ. Harmonization of infliximab and anti-infliximab assays facilitates the comparison between originators and biosimilars in clinical samples. Inflamm Bowel Dis. 2016;22(4):969\u201375. https:\/\/doi.org\/10.1097\/MIB.0000000000000709 .","journal-title":"Inflamm Bowel Dis"},{"key":"177_CR54","unstructured":"Vena-Shores G. Prometheus diagnostic test validated in anticipation of U.S. healthcare provider demand for Celltrion\u2019s INFLECTRA\u2122 (Biosimilar Infliximab): Prometheus Labs; 2016 [Available from: https:\/\/www.prometheuslabs.com\/news\/Article.aspx?ID=66 ."}],"container-title":["Current Treatment Options in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11938-018-0177-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-018-0177-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-018-0177-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:34:08Z","timestamp":1751416448000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11938-018-0177-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["177"],"URL":"https:\/\/doi.org\/10.1007\/s11938-018-0177-z","relation":{},"ISSN":["1092-8472","1534-309X"],"issn-type":[{"value":"1092-8472","type":"print"},{"value":"1534-309X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"1 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Frank I. Scott has received a grant from Takeda Pharmaceuticals and has received personal fees from Janssen Pharmaceuticals and Merck Pharmaceuticals.Gary R. Lichtenstein has received personal fees from Abbvie, Actavis, Alaven, Ironwood, Gilead, Hospira, Luitpold\/American Regent, Merck, McMahon Publishing, Prometheus Laboratories, Romark, Salix Pharmaceuticals\/Valent, Shire Pharmaceuticals, SLACK, Inc., Springer Science and Business Media, UCB, and Up-To-Date. Dr. Lichtenstein has also received grants and personal fees from Celgene, Janssen Ortho Biotech, Pfizer Pharmaceuticals, and Takeda, and honorarium payments from Clinical Advances in Gastroenterology and Gastroenterology and Hepatology (Gastro-Hep Communications).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}